Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$65.41M-76.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Phillip Frost
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 2,275
- Beta
- 1.53
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.40
Financials
Revenue
$65.41M-76.3%Net Income
$-53.53MEBITDA
$-1.69MFree Cash Flow
$-39.10M-235.9%EPS (diluted)
$-0.07Shares Outstanding (diluted)
746.48M+33.8%Operating Expenses
$57.01MCash & Debt
$390.22MReturn of Capital
$10.63MRevenue by Segment (annual)
$606.88MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $606.88M | $-225.68M | $-0.30 |
| 2024 | $713.14M | $-53.22M | $-0.08 |
| 2023 | $863.50M | $-188.86M | $-0.25 |
| 2022 | $1.00B | $-328.40M | $-0.46 |
| 2021 | $1.77B | $-30.14M | $-0.05 |
| 2020 | $1.44B | $30.59M | $0.05 |
| 2019 | $901.93M | $-314.93M | $-0.53 |
| 2018 | $990.30M | $-153.04M | $-0.27 |
| 2017 | $966.01M | $-305.25M | $-0.55 |
| 2016 | $1.22B | $-48.36M | $-0.05 |
| 2015 | $491.70M | $-30.03M | $-0.06 |
| 2014 | $91.10M | $-171.67M | $-0.41 |
| 2013 | $96.53M | $-114.41M | $-0.32 |
| 2012 | $47.04M | $-29.05M | $-0.11 |
Valuation
OPKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (16)
- Newszacks.com·4d ago·Negative
Here's Why You Should Retain OPK Stock in Your Portfolio for Now OPKO Health's Global Products growth, partnered therapies and advancing pipeline support its outlook, but clinical risks and market headwinds pose challenges.
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What OPKO Health (OPK) Said on Its Q3 Earnings Call OPKO Health NASDAQ: OPK reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Negative
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates OPKO Health (OPK) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.03 per share a year ago.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. Third Quarter 2026 and Recent Business Highlights OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.
View source ↗ - Newszacks.com·55d ago·Neutral
Here's Why You Should Retain OPK Stock in Your Portfolio for Now OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
View source ↗ - Newszacks.com·62d ago·Positive
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026? OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
View source ↗ - Newsmarketbeat.com·72d ago·Neutral
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
View source ↗ - Newszacks.com·88d ago·Neutral
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report? OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·90d ago·Neutral
Here's Why You Should Retain OPK Stock in Your Portfolio for Now OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
View source ↗ - Newszacks.com·95d ago·Neutral
OPK Raises $125 Million Against Royalties: What Investors Should Know OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
View source ↗ - Newszacks.com·95d ago·Neutral
Is OPK Worth Buying as Valuation Meets Improving Business Trends? OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
View source ↗ - Newszacks.com·95d ago·Neutral
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going? OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
View source ↗ - Newszacks.com·96d ago·Positive
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.07 per share
Typical surprise +26.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.05 vs $-0.07beat
- Mon, Jul 27$-0.01 vs $-0.08beat
- Tue, Apr 28$-0.07 vs $-0.07beat
- Thu, Feb 26$-0.04 vs $-0.07beat
- Wed, Oct 29$0.03 vs $-0.02beat
- Thu, Jul 31$-0.19 vs $-0.12miss
Estimates and results for OPK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OPK officers and directors.
- Bought
- $9.2m
- Sold
- $25k
54 trades
2 trades
- Paganelli John Asold
- Paganelli John Asold
- Paganelli John Abought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
- Frost Phillip Md Et Albought
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OPK.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
